Tirzepatide, blood pressure, cholesterol

PLoS One published a post hoc analysis of the SURMOUNT trials on 13 August 2026^[1]. It scores tirzepatide against a target that bundles three separate measurements into one pass-or-fail result. A participant counted as a success only if they lost a set share of body weight, dropped their systolic blood pressure by at least 5 mmHg, and finished with a non-HDL cholesterol reading below 130 mg/dL. Missing any one of them scored a zero.

What a composite endpoint is

A composite endpoint is a single scoreboard assembled from several different measurements. Instead of reporting how many people lost 10% of their body weight, you report how many did that and cleared two other bars at the same time. All three conditions had to be true in the same person.

Two of the terms need glossing. Systolic blood pressure is the upper number in a blood pressure reading. Non-HDL cholesterol is total cholesterol with the HDL portion subtracted out, leaving the particle types most associated with artery disease. Both are readings taken at a clinic visit, not events that happened to anyone.

Bundling changes the arithmetic in a way worth sitting with. Each added condition can only shrink the success rate, because everyone who fails the new bar drops out of the count. That makes the numbers look smaller than the single-endpoint weight results readers know from the tirzepatide trial record. It also crushes the placebo arm, which rarely clears three bars by chance. The gap between arms widens even as the absolute numbers fall.

What the analysis actually covered

The authors pooled participants from SURMOUNT-1 through SURMOUNT-4 who had a valid baseline plus at least one post-baseline reading for all three measures^[1]. Analysis populations were 2,345 people in SURMOUNT-1, 879 in SURMOUNT-2, 515 in SURMOUNT-3 and 570 in SURMOUNT-4^[2]. The trials administered tirzepatide at 5 mg, 10 mg and 15 mg weekly, or a maximum tolerated dose of 10 mg or 15 mg.

SURMOUNT-1 is the anchor trial in the group. Its registry record describes a randomised, double-blind, placebo-controlled design in 2,539 adults, running from 4 December 2019 to primary completion on 1 April 2022, with percent change in body weight at week 72 as the primary outcome^[3]. Entry required a BMI of 30 or above, or 27 with a weight-related condition. People with diabetes were excluded. Our tirzepatide safety notes cover the adverse-event profile.

SURMOUNT-4 is built differently and the difference is easy to miss. Everyone took open-label tirzepatide for 36 weeks first, and only then were 783 adults randomised to continue or switch to placebo, with the primary readout at week 88^[4]. Its placebo arm is therefore a group of people who had already lost weight on the drug. The other three trials were assessed at week 72.

The numbers

At the lowest weight bar, 32% to 38% of tirzepatide participants across the trials cleared all three targets, against 2% to 8% on placebo^[1]. Raise the weight bar to at least 10% and the tirzepatide range becomes 28% to 37%, with placebo at 1% to 5%. At the toughest bar, at least 15% body weight reduction, the drug ran 22% to 34% and placebo 1% to 3%. Every between-treatment odds ratio reached p<0.001.

The SURMOUNT-4 placebo group behaved unlike the others, exactly as its design predicts. Among participants who switched to placebo after the 36-week open-label lead-in, 14%, 10% and 8% still met the composite at the three successive weight bars^[2]. Those participants were coasting on weight already lost, so that arm reads as a withdrawal comparison rather than a clean placebo. It is one reason the tirzepatide record on maintenance needs reading separately from the initial-loss trials.

A threshold cleared is not an event prevented

This is the part that gets lost when a result like this travels. Nobody in this analysis was counted for avoiding a heart attack or a stroke. They were counted for a cuff reading and a lipid panel. Blood pressure and cholesterol values are surrogate markers, which means they stand in for cardiovascular risk rather than measuring what happened to anyone. The distinction is the same one we apply to semaglutide results.

The thresholds come from population evidence, and the authors are open about the chain of reasoning. They cite a meta-analysis suggesting a 5 mmHg systolic reduction may lower the risk of major adverse cardiovascular events by roughly 10%, plus endocrinology guidance putting non-HDL cholesterol below 130 mg/dL for people at moderate to high risk of atherosclerotic disease^[2]. Those are reasonable bars to pick, and they remain a proxy for benefit rather than a demonstration of it.

For contrast, look at what a hard endpoint trial counts. SURMOUNT-MMO randomised 15,374 adults with obesity to tirzepatide or placebo under double-blind conditions, and its primary outcome is time to first occurrence of all-cause death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularisation or a heart failure event over up to five years^[5]. That trial is also a composite, but every component is something that happened to a patient. Primary completion is estimated for October 2027. Until then, the honest description of the tirzepatide evidence base on cardiovascular benefit in obesity is that it is pending.

The caveats the authors put in writing

The limitations section is unusually direct. The authors describe the work as post hoc, not adjusted for multiplicity, and intended to be read solely as exploratory and hypothesis-generating^[2]. They advise caution because the composite mixes risk-factor changes with absolute target values, and they flag the differing designs, durations and populations pooled into one analysis.

One caveat in particular deserves surfacing. Systolic blood pressure and non-HDL cholesterol were already relatively normal at baseline here, which the authors say may have attenuated the improvement seen and could limit how far the results generalise to a higher-risk group^[2]. Eli Lilly and Company funded the work. Five of the seven authors are Lilly employees and shareholders, and the lead academic author reports consulting or speaker fees from companies including Lilly.

What the label permits

US labelling has not moved, and that is the practical check on how far any of this can be read. The Zepbound prescribing information revised in April 2026 lists two indications: reducing excess body weight and maintaining that reduction in adults with obesity or overweight plus a weight-related condition, and treating moderate to severe obstructive sleep apnoea in adults with obesity^[6]. Neither a blood pressure indication nor a cholesterol indication appears anywhere in that section, which is the gap the tirzepatide regulatory summary tracks.

Prescription status is unchanged across the markets we track, including the United States, the United Kingdom, Germany and Denmark. Anyone comparing this readout against the semaglutide programme should note that no head-to-head trial applied this composite to both drugs.

What to watch next

SURPASS-CVOT is the nearer signal. The authors report it showed tirzepatide was noninferior to dulaglutide for a composite of death from cardiovascular causes, myocardial infarction or stroke in people with type 2 diabetes and atherosclerotic disease^[2]. The comparator is worth reading carefully, because noninferior to another incretin drug is a different statement from superior to placebo. That trial also enrolled a diabetes population rather than the obesity population studied here.

After that, SURMOUNT-MMO in late 2027 is the readout that would convert surrogate improvements into counted events^[5]. Expect the triple endpoint framing in marketing and conference decks well before then, because it produces a wide separation from placebo. The framing is defensible on its own terms. The claim it cannot yet support is that tirzepatide prevents cardiovascular events in people with obesity and no diabetes.

Medical disclaimer: this article is for educational and journalistic purposes only and does not constitute medical advice. Tirzepatide is a prescription medicine in every market we cover. If you are managing obesity, blood pressure or cholesterol, that conversation belongs with a qualified healthcare professional who knows your history. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.